Pharmaceutical Product Development met Wall Street analyst expectations with earnings of $42 million, or 35 cents a share, for its most recent quarter.

Revenues climbed to $300.2 million, up some $43 million for the same quarter in 2006.

Analysts had told Thomson Financial they expected a 35-cent per share profit on revenues of just over $313 million.

PPD (NASDAQ: PPDI) shares closed at $34.93 on Tuesday.